Histogenics, operating under the name Ocugen, Inc., is a biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies aimed at curing blindness diseases. The company focuses on retinal disorders, including Dry Age-Related Macular Degeneration and Inherited Retinal Disorders such as Retinitis Pigmentosa. Ocugen's innovative gene therapy platform has the potential to treat multiple retinal diseases with a single drug, offering a significant advantage over existing treatments. The company's novel biologic product candidates are designed to provide better therapeutic options for patients suffering from underserved diseases like wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Ocugen serves a global market, targeting patients with rare and underserved eye conditions. The business model revolves around the development and commercialization of its proprietary therapies, generating revenue through product sales, partnerships, and licensing agreements.

Keywords: gene therapy, retinal disorders, blindness, biopharmaceutical, macular degeneration, diabetic retinopathy, innovative therapies, ocular biotherapeutics, rare diseases, transformative treatments.